Hologic (NASDAQ:HOLX) Issues FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.250-4.350 for the period, compared to the consensus EPS estimate of 4.250. The company issued revenue guidance of $4.1 billion-$4.1 billion, compared to the consensus revenue estimate of $4.2 billion. Hologic also updated its Q2 2025 guidance to 1.000-1.030 EPS.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $6.35 during trading on Thursday, hitting $66.45. 3,652,659 shares of the company were exchanged, compared to its average volume of 2,341,251. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a 52-week low of $65.87 and a 52-week high of $84.67. The company has a market cap of $15.00 billion, a PE ratio of 19.96, a P/E/G ratio of 2.35 and a beta of 0.97. The stock has a 50 day moving average of $72.91 and a 200 day moving average of $77.95.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, equities research analysts predict that Hologic will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HOLX. Raymond James increased their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Jefferies Financial Group started coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. Wolfe Research started coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Nine analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.46.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.88% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.